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LETTER TO THE EDITOR
An oncolytic parasite to treat polycythemia vera
I
n recent years, there has been a surge of clinical trials
to treat various kinds of cancers with non-replicating
versions of viruses (1). The most famous among these
is the recent use of a genetically engineered poliovirus used
to treat one of the most difficult-to-treat and recurring
cancers  Glioblastoma Multiforme (2, 3). In addition,
various other modified viruses are being exploited to treat
melanoma, lymphoma, and other tumors. To the best of
our knowledge, there has been no report on the potential
use of oncolytic parasites in the treatment of cancer.
Here, we propose the use of a non-pathogenic strain of
Plasmodium knowlesi to treat primary polycythemia vera
(PV) or other myeloproliferative diseases (4). P. knowlesi
was widely used to treat syphilis before the advent of
penicillin (5, 6).
A PV is a chronic myeloproliferative disorder of the
total bone marrow without any evidence of invasiveness,
in which erythrocytosis, leukocytosis, and thrombocytosis
are simultaneously present (4, 7, 8). PV is a hematopoietic
stem cell disorder characterized by a pan hyperplastic and
neoplastic bone marrow and is classified as a myelo-
proliferative disease. Polycythemia vera, also known as
polycythemia rubra vera (PRV), is characterized by an
elevated absolute red blood cell (RBC) mass because of
unrestrained RBC production. The gold standard for
therapy is systematic phlebotomy (8). In refractory cases,
radioactive phosphorus is used (8). However, the radio-
active therapy carries its own side effects (8).
Similar to oncolytic viruses that enter a specific his-
tological tumor cell type(s) that expresses a well-defined
entry receptor(s) for the virus, P. knowlesi also targets
RBC (9, 10). This oncolytic parasitic treatment for PRV
may be looked upon as an innovative treatment of the
21st century since most contemporary physicians may be
unaware of it.
The Plasmodium-based treatment can be administered
by intravenous injection of the cultured P. knowlesi as
needed and it is non-pathogenic to humans. The parasite
causes a high fever infecting RBC and, after few 24-h
cycles of replication, self-terminates without any treatment.
This parasite was used routinely from 1937 to mid-1950s
to cure syphilis. In the pre-antibiotic era, the goal of
‘malariotherapy’ was to cause high fever that killed
Treponema pallidum. This procedure can be repeated
every few months, eliminating the need for phlebotomy.
The treatment has high potential, in particular, in devel-
oping nations and remote rural areas of the globe where
phlebotomy, using non-sterile needles, is commonplace.
Clearly, during the latter, post-phlebotomy infection can
become problematic. Lyophilized Plasmodium parasites
can survive for years in a dry and non-refrigerated envi-
ronment, and may be quickly hydrated by sterile water
prior to their injection. The high fever, generally associa-
ted with parasitemia, can be dampened by anti-pyretics,
since the purpose of this innovative proposed therapy is
not to cause high fever but to lyse RBC and reduce RBC
overload to near normal. It is probable that this treat-
ment may temporarily cause anemia in some individuals.
Since the underlying pathology being a myeloprolifera-
tive disorder resulting in excess RBC production, anemia
may not be severe or it may not even occur (13, 11). The
treatment may also be associated with hepatosplenome-
galy. This may occur as a result of increased activity of
reticuloendothelial system in an attempt to phagocytize
infected RBCs. Another potential adverse effect with
‘malariotherapy’ may be hemoglobinurea secondary to
hemolysis resulting from lysed parasitized RBCs. Hemo-
globinurea can culminate in acute tubular necrosis caus-
ing renal damage. In case of the latter, cautious fluid intake
is usually sufficient to reverse any renal impairment.
Historic use of P. knowlesi
Plasmodiums of various species have been in use to treat
syphilis since 1917. In 1917, Julius Wagner von Jauregg
was the first to use a benign Plasmodium vivax to treat
syphilis (11). This was originally inspired by the discovery
of Schaudinn (5) that the causative agent of human
syphilis, T. pallidum, was temperature sensitive and the
spirochetes could be killed at several degrees above the
normal human body temperature of 98.68F (5, 11). Thus,
an elevated temperature that was tolerable to humans
but killed T. pallidum was identified (5, 11). von Jauregg
hypothesized that if humans suffering from syphilis were
infected with malaria, the increase in body temperature
to 1048F would cure this disease. To test his hypothesis,
von Jauregg began treating syphilitic patients in efforts to
induce high fever every 48-h (11). This stroke of brilliance
was right on the mark, since this parasite is an excellent
pyrogenic agent that can be controlled easily by treating
the parasite with anti-malarial agents, such as quinine,
that were readily available at that time. This ‘malario-
therapy’ won a Nobel Prize in 1927 for its discoverer, was
effective, but there were logistic issues! The major one was
the lack of a regular supply of the parasite. In 1917,
neither freezers nor lyophilization techniques were avail-
able, nor were available any appropriate animal models or
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cell culture methods that would have enabled maintenance
of a constant supply of the parasites. One needed a better
source of P. vivax other than the human ‘volunteers’ that
were employed as hosts (5, 11). This was really challen-
ging because it was difficult to keep the ‘volunteers’ in a
state of fever on a regular basis, since unless they had para-
sitemia, live parasites could not be isolated from their
blood. An unexpected discovery solved this problem. In
1932, when India was still a British colony, scientists in
Calcutta School of Tropical Medicine discovered that the
Malayan irus monkey was a natural host to a species of
Plasmodium (later named P. knowlesi, after its discoverer
Robert Knowles) that caused no apparent illness. How-
ever, if inoculated to Indian rhesus monkeys or humans,
the parasites can cause mild malaria and were pyogenic.
In humans, this new parasite replicates in blood, with
regular 24-h high-fever cycles, and self-terminates with-
out treatment. This new erythrocytic parasite became an
ideal pyogenic treatment for syphilis. In the 1920s and
1950s, there were many clinics worldwide that practiced
‘malariotherapy’ for syphilis, and in 1937 a well-known
clinic in Bucharest, Romania, initiated the first large-
scale malariotherapy for syphilis with P. knowlesi and
continued the therapy until the 1950s when penicillin
became a routine mode of therapy for syphilis and other
infections (5, 11). In addition, many other clinics used
‘malariotherapy’ on a large scale to treat syphilis. For
example, in England’s Horton Hospital alone, there were
over 10,000 patients who were treated with Plasmodium
between the 1920s and 1950s (5, 11).
Our present hypothesis, to treat the refractory cases of
PV, was prompted by the current surge of virotherapy for
various kinds of neoplasia. There is a surge of research
and clinical trials using genetically engineered oncolytic
viruses to treat different kinds of cancers (13, 12). We
believe that it will not be long before new genetically
engineered oncolytic bacteria, bacteriophages, and other
microorganisms will be available as oncolytic agents for
various types of cancers. As opposed to oncolytic viruses
where generally no antiviral agents may be available,
antibiotics of various kinds can curtail oncolytic bacteria
and parasites.
Accordingly, we propose that anti-cancer therapy should
not be limited to oncolytic viruses but extended to other
microorganisms as well as bacteriophages that can be
readily utilized to treat many chronic neoplastic diseases,
including PV. We forward the hypothesis that human
PRV, a form of RBC neoplasia, can be treated with a non-
pathogenic strain of Plasmodium  P. knowlesi, which can
be described as an oncolytic parasite.
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